$1069.74
6.140.58%
At Close: -
$1069.74
00.00%
After Hours: 4:00 PM EDT
15 minutes delayed
Comments
Loading...
Regeneron Pharmaceuticals
REGNNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock, Analyst Ratings, Price Targets, Forecasts
Regeneron Pharmaceuticals Inc has a consensus price target of $1022.76 based on the ratings of 31 analysts. The high is $1229 issued by RBC Capital on June 24, 2024. The low is $650 issued by B of A Securities on March 29, 2023. The 3 most-recent analyst ratings were released by Cantor Fitzgerald, Piper Sandler, and Guggenheim on July 22, 2024, July 19, 2024, and July 18, 2024, respectively. With an average price target of $1115.33 between Cantor Fitzgerald, Piper Sandler, and Guggenheim, there's an implied 4.26% upside for Regeneron Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Cantor Fitzgerald
Piper Sandler
Guggenheim
Morgan Stanley
Barclays
1calculated from analyst ratings
Analyst Ratings for Regeneron Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/22/2024 | Buy Now | -6.52% | Cantor Fitzgerald | Olivia Brayer | $925 → $1000 | Maintains | Neutral | Get Alert |
| 07/19/2024 | Buy Now | 9% | Piper Sandler | Christopher Raymond | $1000 → $1166 | Maintains | Overweight | Get Alert |
| 07/18/2024 | Buy Now | 10.31% | Guggenheim | Yatin Suneja | $1040 → $1180 | Maintains | Buy | Get Alert |
| 07/11/2024 | Buy Now | 10.49% | Morgan Stanley | Matthew Harrison | $1183 → $1182 | Maintains | Overweight | Get Alert |
| 07/10/2024 | Buy Now | 12.18% | Barclays | Carter Gould | $1050 → $1200 | Maintains | Overweight | Get Alert |
| 06/27/2024 | Buy Now | 7.69% | Canaccord Genuity | John Newman | $1152 → $1152 | Maintains | Buy | Get Alert |
| 06/25/2024 | Buy Now | 9.37% | Argus Research | Jasper Hellweg | $1060 → $1170 | Maintains | Buy | Get Alert |
| 06/24/2024 | Buy Now | 14.89% | RBC Capital | Brian Abrahams | $1229 → $1229 | Reiterates | Outperform → Outperform | Get Alert |
| 06/17/2024 | Buy Now | 7.5% | JP Morgan | Chris Schott | $1050 → $1150 | Maintains | Overweight | Get Alert |
| 06/12/2024 | Buy Now | 14.89% | RBC Capital | Brian Abrahams | $1200 → $1229 | Maintains | Outperform | Get Alert |
| 06/04/2024 | Buy Now | 12.18% | RBC Capital | Brian Abrahams | $1185 → $1200 | Maintains | Outperform | Get Alert |
| 05/14/2024 | Buy Now | 7.5% | Evercore ISI Group | Cory Kasimov | → $1150 | Initiates | → Outperform | Get Alert |
| 05/03/2024 | Buy Now | -13.53% | Cantor Fitzgerald | Olivia Brayer | → $925 | Reiterates | Neutral → Neutral | Get Alert |
| 04/24/2024 | Buy Now | -3.71% | TD Cowen | Tyler Van Buren | $1020 → $1030 | Maintains | Buy | Get Alert |
| 04/17/2024 | Buy Now | 2.74% | UBS | Colin Bristow | $1090 → $1099 | Maintains | Buy | Get Alert |
| 04/17/2024 | Buy Now | -13.53% | Cantor Fitzgerald | Olivia Brayer | → $925 | Reiterates | Neutral → Neutral | Get Alert |
| 04/15/2024 | Buy Now | -13.53% | Cantor Fitzgerald | Louise Chen | → $925 | Reiterates | Neutral → Neutral | Get Alert |
| 04/12/2024 | Buy Now | -32.69% | B of A Securities | Geoff Meacham | $710 → $720 | Maintains | Underperform | Get Alert |
| 04/09/2024 | Buy Now | 11.15% | RBC Capital | Brian Abrahams | → $1189 | Reiterates | Outperform → Outperform | Get Alert |
| 04/03/2024 | Buy Now | 6.1% | Truist Securities | Robyn Karnauskas | $1135 → $1135 | Maintains | Buy | Get Alert |
| 03/26/2024 | Buy Now | 6.1% | Truist Securities | Robyn Karnauskas | $1135 → $1135 | Maintains | Buy | Get Alert |
| 03/13/2024 | Buy Now | 4.23% | Morgan Stanley | Matthew Harrison | $1104 → $1115 | Maintains | Overweight | Get Alert |
| 03/12/2024 | Buy Now | 5.17% | Bernstein | William Pickering | → $1125 | Initiates | → Outperform | Get Alert |
| 03/11/2024 | Buy Now | 5.17% | Bernstein | Aaron Gal | → $1125 | Initiates | → Outperform | Get Alert |
| 02/27/2024 | Buy Now | 10.68% | RBC Capital | Brian Abrahams | $1096 → $1184 | Maintains | Outperform | Get Alert |
| 02/06/2024 | Buy Now | -13.53% | Cantor Fitzgerald | Olivia Brayer | $850 → $925 | Maintains | Neutral | Get Alert |
| 02/05/2024 | Buy Now | 3.76% | RBC Capital | Brian Abrahams | $1076 → $1110 | Maintains | Outperform | Get Alert |
| 02/05/2024 | Buy Now | 1.15% | BMO Capital | Evan David Seigerman | $1055 → $1082 | Maintains | Outperform | Get Alert |
| 01/29/2024 | Buy Now | 0.59% | RBC Capital | Brian Abrahams | → $1076 | Reiterates | Outperform → Outperform | Get Alert |
| 01/23/2024 | Buy Now | -4.65% | Barclays | Carter Gould | $935 → $1020 | Maintains | Overweight | Get Alert |
| 01/12/2024 | Buy Now | 0.59% | RBC Capital | Brian Abrahams | → $1076 | Upgrade | Sector Perform → Outperform | Get Alert |
| 01/09/2024 | Buy Now | -20.54% | Cantor Fitzgerald | Olivia Brayer | → $850 | Reiterates | Neutral → Neutral | Get Alert |
| 12/18/2023 | Buy Now | -2.31% | Truist Securities | Robyn Karnauskas | → $1045 | Reiterates | Buy → Buy | Get Alert |
| 12/06/2023 | Buy Now | -6.52% | TD Cowen | Tyler Van Buren | $900 → $1000 | Maintains | Outperform | Get Alert |
| 11/29/2023 | Buy Now | -2.31% | Truist Securities | Robyn Karnauskas | → $1045 | Reiterates | Buy → Buy | Get Alert |
| 11/28/2023 | Buy Now | -12.41% | Jefferies | Akash Tewari | $935 → $937 | Maintains | Buy | Get Alert |
| 11/28/2023 | Buy Now | -2.31% | Truist Securities | Robyn Karnauskas | → $1045 | Reiterates | Buy → Buy | Get Alert |
| 11/09/2023 | Buy Now | -25.22% | Deutsche Bank | James Shin | → $800 | Initiates | → Hold | Get Alert |
| 11/03/2023 | Buy Now | -16.33% | Piper Sandler | Christopher Raymond | $885 → $895 | Maintains | Overweight | Get Alert |
| 11/03/2023 | Buy Now | -21.76% | RBC Capital | Brian Abrahams | $847 → $837 | Maintains | Sector Perform | Get Alert |
| 11/03/2023 | Buy Now | -14.56% | Morgan Stanley | Matthew Harrison | $915 → $914 | Maintains | Overweight | Get Alert |
| 11/03/2023 | Buy Now | -11.19% | Raymond James | Dane Leone | → $950 | Upgrade | Market Perform → Outperform | Get Alert |
| 10/16/2023 | Buy Now | -20.54% | Cantor Fitzgerald | Alethia Young | $800 → $850 | Maintains | Neutral | Get Alert |
| 10/12/2023 | Buy Now | -20.82% | RBC Capital | Brian Abrahams | $833 → $847 | Maintains | Sector Perform | Get Alert |
| 10/11/2023 | Buy Now | -14.47% | Morgan Stanley | Matthew Harrison | $912 → $915 | Maintains | Overweight | Get Alert |
| 09/21/2023 | Buy Now | -25.22% | Cantor Fitzgerald | Alethia Young | → $800 | Reiterates | Neutral → Neutral | Get Alert |
| 09/15/2023 | Buy Now | -14% | Argus Research | Jasper Hellweg | $825 → $920 | Maintains | Buy | Get Alert |
| 09/15/2023 | Buy Now | — | WestPark Capital | — | — | Initiates | → Hold | Get Alert |
| 08/21/2023 | Buy Now | -7.27% | Canaccord Genuity | John Newman | $720 → $992 | Upgrade | Hold → Buy | Get Alert |
| 08/21/2023 | Buy Now | -8.39% | Wells Fargo | Mohit Bansal | $875 → $980 | Maintains | Overweight | Get Alert |
| 08/21/2023 | Buy Now | -2.31% | Truist Securities | Robyn Karnauskas | → $1045 | Reiterates | Buy → Buy | Get Alert |
| 08/21/2023 | Buy Now | -1.85% | Oppenheimer | Hartaj Singh | $950 → $1050 | Maintains | Outperform | Get Alert |
| 08/21/2023 | Buy Now | -22.41% | RBC Capital | Brian Abrahams | $820 → $830 | Maintains | Sector Perform | Get Alert |
| 08/21/2023 | Buy Now | -7.92% | BMO Capital | Evan David Seigerman | $960 → $985 | Maintains | Outperform | Get Alert |
| 08/21/2023 | Buy Now | -13.53% | Barclays | Carter Gould | $900 → $925 | Maintains | Overweight | Get Alert |
| 08/18/2023 | Buy Now | -32.69% | Canaccord Genuity | John Newman | $720 → $720 | Maintains | Hold | Get Alert |
| 08/16/2023 | Buy Now | -2.31% | Truist Securities | Robyn Karnauskas | → $1045 | Reiterates | Buy → Buy | Get Alert |
| 08/07/2023 | Buy Now | -15.87% | Barclays | Carter Gould | $888 → $900 | Maintains | Overweight | Get Alert |
| 08/04/2023 | Buy Now | -14.75% | Morgan Stanley | Matthew Harrison | $897 → $912 | Maintains | Overweight | Get Alert |
| 08/04/2023 | Buy Now | -23.35% | RBC Capital | Brian Abrahams | $818 → $820 | Maintains | Sector Perform | Get Alert |
| 08/04/2023 | Buy Now | -11.19% | Oppenheimer | Hartaj Singh | $900 → $950 | Maintains | Outperform | Get Alert |
| 07/17/2023 | Buy Now | -15.87% | Guggenheim | Yatin Suneja | $935 → $900 | Maintains | Buy | Get Alert |
| 07/11/2023 | Buy Now | -16.15% | Morgan Stanley | Matthew Harrison | $927 → $897 | Maintains | Overweight | Get Alert |
| 07/06/2023 | Buy Now | -25.68% | Cantor Fitzgerald | Alethia Young | $815 → $795 | Maintains | Neutral | Get Alert |
| 06/28/2023 | Buy Now | -2.31% | Truist Securities | Robyn Karnauskas | $1050 → $1045 | Maintains | Buy | Get Alert |
| 06/28/2023 | Buy Now | -28.95% | Baird | Brian Skorney | $800 → $760 | Maintains | Neutral | Get Alert |
| 06/28/2023 | Buy Now | -26.24% | RBC Capital | Brian Abrahams | $816 → $789 | Maintains | Sector Perform | Get Alert |
| 06/28/2023 | Buy Now | -16.99% | Barclays | Carter Gould | $915 → $888 | Maintains | Overweight | Get Alert |
| 06/28/2023 | Buy Now | -32.69% | Canaccord Genuity | John Newman | $953 → $720 | Downgrade | Buy → Hold | Get Alert |
| 06/27/2023 | Buy Now | -1.85% | Truist Securities | Robyn Karnauskas | → $1050 | Reiterates | Buy → Buy | Get Alert |
| 06/27/2023 | Buy Now | -23.72% | RBC Capital | Brian Abrahams | → $816 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 06/23/2023 | Buy Now | -23.81% | Cantor Fitzgerald | Alethia Young | → $815 | Reiterates | Neutral → Neutral | Get Alert |
| 06/20/2023 | Buy Now | -23.81% | Cantor Fitzgerald | Alethia Young | → $815 | Reiterates | Neutral → Neutral | Get Alert |
| 06/09/2023 | Buy Now | -23.72% | RBC Capital | Brian Abrahams | $811 → $816 | Maintains | Sector Perform | Get Alert |
| 05/16/2023 | Buy Now | -24.19% | RBC Capital | Brian Abrahams | → $811 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 05/08/2023 | Buy Now | -12.6% | Guggenheim | Yatin Suneja | $960 → $935 | Maintains | Buy | Get Alert |
| 05/05/2023 | Buy Now | -24.19% | RBC Capital | Brian Abrahams | $830 → $811 | Maintains | Sector Perform | Get Alert |
| 05/05/2023 | Buy Now | -13.34% | Morgan Stanley | Matthew Harrison | $880 → $927 | Maintains | Overweight | Get Alert |
| 05/03/2023 | Buy Now | -1.85% | Truist Securities | Robyn Karnauskas | $856 → $1050 | Maintains | Buy | Get Alert |
| 05/01/2023 | Buy Now | -19.42% | EF Hutton | Michael King | → $862 | Reiterates | → Buy | Get Alert |
| 04/20/2023 | Buy Now | -17.27% | TD Cowen | Tyler Van Buren | $875 → $885 | Maintains | Outperform | Get Alert |
| 03/31/2023 | Buy Now | -11.19% | JP Morgan | Chris Schott | $900 → $950 | Maintains | Overweight | Get Alert |
| 03/29/2023 | Buy Now | -39.24% | B of A Securities | Elizabeth Suzuki | $605 → $650 | Maintains | Underperform | Get Alert |
| 03/28/2023 | Buy Now | — | Erste Group | Hans Engel | — | Reinstates | → Buy | Get Alert |
| 03/27/2023 | Buy Now | -8.76% | SVB Leerink | David Risinger | $834 → $976 | Upgrade | Market Perform → Outperform | Get Alert |
| 03/24/2023 | Buy Now | -2.78% | BMO Capital | Evan David Seigerman | $1025 → $1040 | Maintains | Outperform | Get Alert |
| 03/24/2023 | Buy Now | -25.22% | Baird | Brian Skorney | $756 → $800 | Maintains | Neutral | Get Alert |
| 03/24/2023 | Buy Now | -14.47% | Wells Fargo | Mohit Bansal | $860 → $915 | Maintains | Overweight | Get Alert |
| 03/24/2023 | Buy Now | -14.47% | Barclays | Carter Gould | $815 → $915 | Maintains | Overweight | Get Alert |
| 03/24/2023 | Buy Now | -13.53% | Jefferies | Akash Tewari | $675 → $925 | Upgrade | Hold → Buy | Get Alert |
| 03/24/2023 | Buy Now | — | Raymond James | Dane Leone | — | Upgrade | Underperform → Market Perform | Get Alert |
| 03/23/2023 | Buy Now | — | Raymond James | Dane Leone | — | Upgrade | Underperform → Market Perform | Get Alert |
| 03/23/2023 | Buy Now | -19.42% | EF Hutton | Michael King | $853 → $862 | Maintains | Buy | Get Alert |
| 03/14/2023 | Buy Now | -4.18% | BMO Capital | Evan Kurtz | $1001 → $1025 | Maintains | Outperform | Get Alert |
| 03/09/2023 | Buy Now | -24.65% | RBC Capital | Brian Abrahams | $787 → $806 | Maintains | Sector Perform | Get Alert |
| 02/24/2023 | Buy Now | -20.26% | EF Hutton | Michael King | → $853 | Reiterates | → Buy | Get Alert |
| 02/21/2023 | Buy Now | -19.61% | Wells Fargo | Mohit Bansal | $800 → $860 | Maintains | Overweight | Get Alert |
| 02/17/2023 | Buy Now | -19.61% | Wells Fargo | Mohit Bansal | $800 → $860 | Maintains | Overweight | Get Alert |
| 02/08/2023 | Buy Now | -20.26% | EF Hutton | Michael King | $851 → $853 | Maintains | Buy | Get Alert |
| 02/06/2023 | Buy Now | -26.43% | RBC Capital | Brian Abrahams | $789 → $787 | Maintains | Sector Perform | Get Alert |
FAQ
What is the target price for Regeneron Pharmaceuticals (REGN) stock?
The latest price target for Regeneron Pharmaceuticals (NASDAQ:REGN) was reported by Cantor Fitzgerald on July 22, 2024. The analyst firm set a price target for $1000.00 expecting REGN to fall to within 12 months (a possible -6.52% downside). 61 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Regeneron Pharmaceuticals (REGN)?
The latest analyst rating for Regeneron Pharmaceuticals (NASDAQ:REGN) was provided by Cantor Fitzgerald, and Regeneron Pharmaceuticals maintained their neutral rating.
When was the last upgrade for Regeneron Pharmaceuticals (REGN)?
The last upgrade for Regeneron Pharmaceuticals Inc happened on January 12, 2024 when RBC Capital raised their price target to $1076. RBC Capital previously had a sector perform for Regeneron Pharmaceuticals Inc.
When was the last downgrade for Regeneron Pharmaceuticals (REGN)?
The last downgrade for Regeneron Pharmaceuticals Inc happened on June 28, 2023 when Canaccord Genuity changed their price target from $953 to $720 for Regeneron Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Regeneron Pharmaceuticals (REGN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Regeneron Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Regeneron Pharmaceuticals was filed on July 22, 2024 so you should expect the next rating to be made available sometime around July 22, 2025.
Is the Analyst Rating Regeneron Pharmaceuticals (REGN) correct?
While ratings are subjective and will change, the latest Regeneron Pharmaceuticals (REGN) rating was a maintained with a price target of $925.00 to $1000.00. The current price Regeneron Pharmaceuticals (REGN) is trading at is $1069.74, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.